PhotonAssay technology is a quantitative, chemistry-free assay solution which can be used to detect a wide range of elements, proving particularly effective for gold. The company operates through EMEA, Australia, and Americas geographical segments. Early commercialization phase with significant growth runway but elevated operating costs.
Cyborg Score Rationale
Recent half-year net income was −5.61 M AUD with negative EBITDA of −49.86 M AUD. The company is pre-profitability with execution risk, though it operates in a high-value market with proprietary differentiation.
Top Insights
Company went IPO on May 6, 2022, establishing public market access for growth funding
As of January 19, 2026, the company has 207 employees, maintaining lean operations during commercialization
Proprietary chemistry-free assay solution addresses significant pain points in global mining industry workflows
Pre-profitability stage with negative EBITDA indicates company is investing heavily in scaling operations
Named Competitors
Traditional Wet Chemistry Assaying — Incumbent assay methods relying on chemical analysis
Ion Beam Analysis — Alternative technology-based assay approach
XRF and ICP-MS Services — Competing analytical technology platforms
Recent Developments
October 2025: Stock reached all-time high of 9.42 AUD, indicating investor optimism on growth trajectory
January 2026: 207 employees on staff, reflecting continued operational expansion
Recent period: Negative net income trajectory with half-year losses of −5.61 M AUD
Open the full interactive Chrysos Corporation Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.